Project Details
Description
KB001A-05, A Phase 2, Randomized, Double-blind, Placebo-controlled, Repeat-dose Study of KB001 A in Subjects with Cystic Fibrosis Infected with Pseudomonas aeruginosa
| Status | Finished |
|---|---|
| Effective start/end date | 11/30/12 → 6/30/15 |
Funding
- KaloBios Pharmaceuticals, Inc.
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.